The effect of P2Y12 receptor inhibitors on clinical outcomes in patients with acute coronary syndrome undergoing primary percutaneous intervention and receiving abciximab
In our study, potent P2Y12 receptor inhibitors combined with abciximab decreased 1-year MACE without significantly increasing bleeding in ACS patients undergoing PCI compared to clopidogrel. This study suggests that potent P2Y12 receptor inhibitors can be safely used with abciximab, considering the bleeding risk.
Authors
- Onur Altınkaya (ORCID: https://orcid.org/0000-0002-2178-6140)
- İbrahim Saraç (ORCID: https://orcid.org/0000-0002-1574-2053)
- Yavuzer Koza (ORCID: https://orcid.org/0000-0002-2824-2701)
- Sidar Şiyar Aydın (ORCID: https://orcid.org/0000-0002-8204-1505)
- Mustafa Özkoç (ORCID: https://orcid.org/0000-0001-7113-3378)
- Emrah Aksakal (ORCID: https://orcid.org/0000-0001-5765-4281)
- Selim Aydemir (ORCID: https://orcid.org/0000-0001-6654-2521)
- Rauf Macit (ORCID: https://orcid.org/0000-0002-3750-4478)
- Murat Özmen (ORCID: https://orcid.org/0000-0002-6237-1398)
- Muhammet Hakan Taş
Institutions
- Sivas State Hospital (TR)
- Erzurum Regional Training and Research Hospital (TR)
- Atatürk University (TR)
- Sinop University (TR)
Publication Details
- Journal
- Cardiology Journal
- Published
- 2025-06-24
- DOI
- https://doi.org/10.5603/cj.104531
- Primary Topic
- Antiplatelet Therapy and Cardiovascular Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00